Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Ailawadhi · SciRah

Researcher profile · Semantic Scholar

S. Ailawadhi

Share profile

S. Ailawadhi — researcher profile on SciRah

h-index: 36
Works: 577
Citations: 5,670

Most-cited papers

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
Ricardo D. Parrondo, S. Ailawadhi, C. Cerchione
2024Frontiers in Oncology21 citations Open access
Semantic Scholar
Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
S. Ailawadhi, Larry D. Anderson, B. Dhakal, Leyla Shune +2 more
2025Clinical Lymphoma, Myeloma & Leukemia12 citations Open access
Semantic Scholar
Risk Factors for Delayed Neurotoxicity in Patients with Relapsed Myeloma Who Received Ciltacabtagene Autoleucel (cilta-cel)
K. Lim, Saurabh Chhabra, Andre De Menezes Silva Corraes, Ricardo D. Parrondo +17 more
2025Transplantation and Cellular Therapy8 citations Open access
Semantic Scholar
Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel.
K. Lim, Ricardo D. Parrondo, Saurabh Chhabra, Katharine E Dooley +16 more
2025Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel)
K. Lim, Saurabh Chhabra, Andre De Menezes Silva Corraes, Ricardo D. Parrondo +16 more
2025Transplantation and Cellular Therapy7 citations Open access
Semantic Scholar
Advances and future directions in radiopharmaceutical delivery for cancer treatment
S. Ailawadhi, D. Pafundi, Jennifer L. Peterson
2025Expert Review of Anticancer Therapy7 citations
Semantic Scholar
Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel
Kenneth J. C. Lim, Hee Eun Lee, Z. Chen, Adam C. Bledsoe +22 more
2026Blood Advances4 citations Open access
Semantic Scholar
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia
S. Zanwar, J. Abeykoon, S. D'Sa, Damien Roos-Weil +25 more
2026Blood Advances4 citations Open access
Semantic Scholar
Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity
Kenneth J. C. Lim, Ricardo D. Parrondo, Saurabh Chhabra, K. Dooley +22 more
2025Blood4 citations
Semantic Scholar
Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study
S. Ailawadhi, Timothy J. Inocencio, Carol Mansfield, Phani Chintakayala +6 more
2025Future Oncology4 citations Open access
Semantic Scholar
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
S. Ailawadhi, I. Špička, Andrew Spencer, Jin Lu +28 more
2025Journal of Clinical Oncology4 citations
Semantic Scholar
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma.
Hans C. Lee, W. Plattel, Simon J. Harrison, Doug Sborov +15 more
2026Blood3 citations Open access
Semantic Scholar
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
S. Ailawadhi, S. Challagulla, T. Totev, D. Pilon +5 more
2026Expert Review of Hematology3 citations Open access
Semantic Scholar
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma.
A. Chari, Susan Bal, S. Ailawadhi, Amrita Y. Krishnan +10 more
2025Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma
E. Ocio, Gurdeep Parmar, María-Victoria Mateos, X. Leleu +10 more
2026Expert Opinion on Drug Delivery2 citations Open access
Semantic Scholar
CAR T-Cell Therapy Outcomes in Plasma Cell Leukemia
Melinda S. Y. Tan, Joselle M. Cook, W. Gonsalves, S. Zanwar +18 more
2026Blood Immunology & Cellular Therapy2 citations Open access
Semantic Scholar
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia
S. Ailawadhi, S. Challagulla, Po-Ya Chuang, W. Furnback +1 more
2026Expert Review of Hematology2 citations Open access
Semantic Scholar
Investigating the Role of Dexamethasone Prophylaxis for the Risk Reduction of Immune Effector Cell Delayed Neurotoxicity in Cilta-Cel Treated Patients
K. Lim, Ricardo D. Parrondo, Saurabh Chhabra, Katharine E. Dooley +22 more
2026Transplantation and Cellular Therapy2 citations
Semantic Scholar
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
C. Tan, Saad Z. Usmani, A. Derkach, Andre De Menezes Silva Corraes +27 more
2026Blood Advances2 citations Open access
Semantic Scholar
Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study
S. Ailawadhi, I. Špička, Jin Lu, A. Oriol +19 more
2025Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)
María-Victoria Mateos, I. Špička, Andrew Spencer, A. Oriol +16 more
2025Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel
S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo +10 more
2025Blood2 citations
Semantic Scholar
Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study
M. Mateos, Silvia Ling, C. Cerchione, P. Rajnics +8 more
2025Blood2 citations
Semantic Scholar
Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)
Krina K. Patel, P. Rodríguez-Otero, A. Nooka, Natalie S. Callander +21 more
2024Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar
KarMMa-3 Subgroup Analysis in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel
S. Ailawadhi, B. Arnulf, Krina K. Patel, M. Cavo +10 more
2026Transplantation and Cellular Therapy1 citations
Semantic Scholar
Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
Kenneth J. C. Lim, Shaji K. Kumar, Ricardo D. Parrondo, Saurabh Chhabra +21 more
2026American journal of hematology/oncology1 citations Open access
Semantic Scholar
Systematic review of frailty, functional status & comorbidities in older adults with multiple myeloma undergoing high dose therapy & autologous stem cell transplant.
N. Abdallah, Ashlyn O'Leary, C. Schmidt, S. Ailawadhi +3 more
2026Journal of Geriatric Oncology1 citations
Semantic Scholar
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.
S. Parikh, P. Hampel, Lindsey E. Roeker, Yu-Cai Wang +21 more
2026Mayo Clinic proceedings1 citations
Semantic Scholar
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA
S. Ailawadhi, Doris K Hansen, B. Dhakal, Leyla Shune +13 more
2026Advances in Therapy1 citations Open access
Semantic Scholar
Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Jin Lu, A. Oriol, A. Berkovits, Andrew Spencer +21 more
2025Blood1 citations
Semantic Scholar
Cancer Care Beyond Walls (CCBW): A randomized pragmatic trial of home-based versus in-clinic cancer therapy administration.
R. Dronca, Jeremy C Jones, Hemant S. Murthy, P. Advani +10 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): Age-related disparity.
Keri Yang, S. Challagulla, Po-Ya Chuang, W. Furnback +1 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies
S. Ailawadhi, Yelak Biru, Solène Clavreul, Maite San Miguel +9 more
2025Patient Preference and Adherence1 citations Open access
Semantic Scholar
CLL-1065: Real-World Treatment Utilization Patterns, Discontinuation, and Healthcare Resource Utilization of First-Line Bruton Tyrosine Kinase Inhibitor Therapy in Chronic Lymphocytic Leukemia: Age-Related Disparity
Keri Yang, S. Challagulla, Po-Ya Chuang, W. Furnback +1 more
2025Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US
S. Ailawadhi, Thomas E. Delea, Olivier Humblet, Timothy J. Inocencio +7 more
2025Blood1 citations
Semantic Scholar
Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
S. Ailawadhi, I. Špička, Jin Lu, A. Oriol +16 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
PA-432 Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials
X. Leleu, C. Cerchione, S. Ailawadhi, J. Minařík +15 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PA-271 Isatuximab Plus Pomalidomide-Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Subgroup Analysis by Prior Anti-CD38 Exposure From the Phase 3 IRAKLIA Trial
A. Oriol, M. Hus, R. Gazitua, Ai-Jun Liao +16 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Impact of adult failure to thrive (AFTT) on inpatient mortality (IM) and resource utilization in patients with gastrointestinal cancer (GIC): A nationwide analysis.
Saurav Das, T. Suenghataiphorn, Harshit Arora, Bilori Bilori +3 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
PA-185 Evaluation of Patient-Reported Outcomes and Subgroup Analysis With Subcutaneous Isatuximab Delivered via On-Body Injector Compared With Intravenous Delivery From the Phase 3 IRAKLIA Trial
Silvia Ling, I. Špička, A. Oriol, A. Berkovits +20 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Real-World Outcomes and Risk Factors in Multiple Myeloma Pts Receiving Cilta-Cel Including Functional High-Risk Status
K. Lim, Ricardo D. Parrondo, Saurabh Chhabra, Katharine E. Dooley +20 more
2026Transplantation and Cellular Therapy0 citations Open access
Semantic Scholar
Impact of prophylactic cyclophosphamide on ALC and delayed neurotoxicity after cilta-cel.
Melinda S. Y. Tan, C. Schaefers, K. Lim, Saurabh Chhabra +16 more
2026Journal of Clinical Oncology0 citations Open access
Semantic Scholar
Burden and survival outcome of secondary malignancies in Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL): A population-based analysis using Surveillance, Epidemiology, and End Results (SEER 2000-2022).
Saurav Das, Harshit Arora, Yifei Zhang, A. Russo +2 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
PA-337 Patient Experience, Satisfaction and Preference with Isatuximab Subcutaneous On-Body Injector from the Phase 3 IRAKLIA and Phase 2 IZALCO Clinical Trials
C. Cerchione, S. Ailawadhi, Silvia Ling, A. Oriol +17 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PA-222 Hematology-Oncologists’ Perspectives on an On-Body Injector for Administration of Large-Volume Subcutaneous Drugs: Implications for Isatuximab Subcutaneous for Multiple Myeloma
C. Tan, Muhamad Baljevic, S. Ailawadhi, Erin Comerford +2 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Quantitative bias analyses to address measurement error in time-to-event endpoints
Benjamin Ackerman, Ryan W. Gan, Youyi Zhang, J. Hayden +15 more
2026American Journal of Epidemiology0 citations Open access
Semantic Scholar
PA-363 Premedication Use and Infusion-Related Reactions in Patients Treated With Subcutaneous Isatuximab: A Pooled Post Hoc Safety Analysis
F. Schjesvold, A. Berkovits, X. Leleu, S. Ailawadhi +16 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Net costs associated with inpatient (IP) administration of step-up dosing (SUD) of bispecific antibodies (bsAbs) among Medicare patients (pts) with relapsed/refractory multiple myeloma (MM).
Nisha S. Joseph, Timothy J. Inocencio, Shannon Heitkamp, Thomas E. Delea +5 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Comparative survival disparities and outcome in primary vs secondary central nervous system lymphoma (CNSL): A population-based analysis using Surveillance, Epidemiology, and End Results (SEER) program (2000-2022).
Harshit Arora, Saurav Das, Lavanya Arora, Bilori Bilori +4 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
POSTER: CLL-476: Real-World Comparative Analysis of Treatment Discontinuation With Covalent Bruton Tyrosine Kinase Inhibitors in First-Line Chronic Lymphocytic Leukemia
N. Saba, Erin Mulvey, Mei Xue, Keri Yang +4 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Ricardo D. Parrondo×17
Invite
Ricardo D. Parrondo — researcher profile on SciRah
Saurabh Chhabra×10
Invite
Saurabh Chhabra — researcher profile on SciRah
R. Warsame×10
Invite
R. Warsame — researcher profile on SciRah
M. Binder×10
Invite
M. Binder — researcher profile on SciRah

Andre De Menezes Silva Corraes

×9

Invite

Andre De Menezes Silva Corraes — researcher profile on SciRah

Morie A. Gertz×9

Invite

Morie A. Gertz — researcher profile on SciRah

Joselle M. Cook×9

Invite

Joselle M. Cook — researcher profile on SciRah

Invite

I. Špička — researcher profile on SciRah

Invite

A. Oriol — researcher profile on SciRah

Gurdeep Parmar×9

Invite

Gurdeep Parmar — researcher profile on SciRah

Maya Stefanova-Urena×9

Invite

Maya Stefanova-Urena — researcher profile on SciRah

Haily Stephens×8

Invite

Haily Stephens — researcher profile on SciRah